PCIA
GSK icon

Prime Capital Investment Advisors’s GSK GSK Stock Holding History

Prime Capital Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Sell
42,227
-16,384
-28% -$866K 0.02% 365
2026
Q1 		$3.23M Buy
58,611
+28,423
+94% +$1.54M 0.04% 289
2025
Q4 		$1.48M Buy
30,188
+19,509
+183% +$910K 0.02% 412
2025
Q3 		$461K Sell
10,679
-132
-1% -$5.16K 0.01% 663
2025
Q2 		$415K Buy
10,811
+924
+9% +$35.3K 0.01% 667
2025
Q1 		$383K Buy
9,887
+569
+6% +$20.8K ﹤0.01% 750
2024
Q4 		$315K Sell
9,318
-35
-0.4% -$1.26K ﹤0.01% 714
2024
Q3 		$382K Sell
9,353
-74
-0.8% -$3.03K 0.01% 661
2024
Q2 		$363K Sell
9,427
-1,470
-13% -$61.8K 0.01% 666
2024
Q1 		$467K Sell
10,897
-528
-5% -$21.8K 0.01% 638
2023
Q4 		$423K Sell
11,425
-1,408
-11% -$50.5K 0.01% 619
2023
Q3 		$465K Sell
12,833
-789
-6% -$28K 0.01% 479
2023
Q2 		$485K Buy
13,622
+269
+2% +$9.65K 0.01% 489
2023
Q1 		$475K Buy
13,353
+2,916
+28% +$102K 0.02% 353
2022
Q4 		$367K Buy
10,437
+3,592
+52% +$120K 0.01% 383
2022
Q3 		$201K Buy
+6,845
New +$259K 0.01% 383
2020
Q4 		– Sell
-109
Closed -$5K – 471
2020
Q3 		$5K Sell
109
-473
-81% -$23.7K ﹤0.01% 418
2020
Q2 		$30K Buy
582
+4
+0.7% +$205 ﹤0.01% 360
2020
Q1 		$27K Sell
578
-2
-0.3% -$107 ﹤0.01% 329
2019
Q4 		$34K Buy
580
+100
+21% +$5.56K ﹤0.01% 347
2019
Q3 		$26K Buy
+480
New +$24.7K ﹤0.01% 385
2019
Q1 		– Sell
-11
Closed -$1K – 363
2018
Q4 		$1K Buy
+11
New +$542 ﹤0.01% 345
2018
Q1 		– Sell
-768
Closed -$34K – 257
2017
Q4 		$34K Buy
+768
New +$35.5K 0.03% 177

Other funds holding GSK

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.24B AUM 11.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prime Capital Investment Advisors's GSK Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its GSK (GSK) stake by 28% in Q2 2026, selling an estimated $866K and leaving 42,227 shares worth $2.21M. The position accounts for 0.02% of the portfolio, ranked #365.

Prime Capital Investment Advisors first reported a position in GSK in Q4 2017 and has held it in 23 quarters since. The position peaked at $3.23M in Q1 2026. 800 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Prime Capital Investment Advisors held 42,227 shares of GSK worth $2.21M as of Q2 2026.
  • Prime Capital Investment Advisors sold 16,384 GSK shares in Q2 2026, an estimated $866K.
  • GSK made up 0.02% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #365 holding.
  • Prime Capital Investment Advisors first reported a position in GSK in Q4 2017 and has held it in 23 quarters since.
  • Prime Capital Investment Advisors's GSK position peaked at $3.23M in Q1 2026.
  • 800 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.